You are here

  • Home
  • Archive
  • Volume 4, Issue 2
  • Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis

Article info

Article menu

Download PDFPDF

Treatments
Original article
Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis

Authors

  • Bente Glintborg The DANBIO registry and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark Department of Rheumatology, Gentofte and Herlev Hospital, Copenhagen University Hospital, Hellerup, Denmark PubMed articlesGoogle scholar articles
  • Jan Sørensen Healthcare Outcome Research Centre, Royal College of Surgeons in Ireland, Dublin, Ireland PubMed articlesGoogle scholar articles
  • Merete Lund Hetland The DANBIO registry and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Bente Glintborg; glintborg{at}dadlnet.dk
View Full Text

Citation

Glintborg B, Sørensen J, Hetland ML
Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis
RMD Open 2018;4:e000710. doi: 10.1136/rmdopen-2018-000710

Publication history

  • Received April 23, 2018
  • Revision received June 4, 2018
  • Accepted June 16, 2018
  • First published July 11, 2018.
Online issue publication 
December 23, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/